Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Buzard

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Medicinal Chemistry|July 20, 2013
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonistsSangdon Han, Jayant Thatte, Daniel J Buzard, et al.
Pharmaceutical Patent Analyst|November 19, 2013
GPR119 agonists 2009-2011Daniel J Buzard, Juerg Lehmann, Sangdon Han, et al.
Expert Opinion on Therapeutic Patents|September 29, 2009
GPR119 agonists for the treatment of type 2 diabetesRobert M Jones, James N Leonard, Daniel J Buzard, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2016
C-H activation reactions as useful tools for medicinal chemistsEduardo J E Caro-Diaz, Mariangela Urbano, Daniel J Buzard, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2010
Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligandsBrad M Savall, James P Edwards, Jennifer D Venable, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2006
Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligandsAlice Lee-Dutra, Kristen L Arienti, Daniel J Buzard, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2013
Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and durationDavid J Unett, Joel Gatlin, Todd L Anthony, et al.
Bioorganic & Medicinal Chemistry Letters|December 24, 2014
Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptorDaniel J Buzard, Thomas O Schrader, Xiuwen Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2014
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonistsDaniel J Buzard, Sun Hee Kim, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist seriesSangdon Han, Sanju Narayanan, Sun Hee Kim, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Medicinal Chemistry|July 20, 2013
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonistsSangdon Han, Jayant Thatte, Daniel J Buzard, et al.
Pharmaceutical Patent Analyst|November 19, 2013
GPR119 agonists 2009-2011Daniel J Buzard, Juerg Lehmann, Sangdon Han, et al.
Expert Opinion on Therapeutic Patents|September 29, 2009
GPR119 agonists for the treatment of type 2 diabetesRobert M Jones, James N Leonard, Daniel J Buzard, et al.
Bioorganic & Medicinal Chemistry Letters|October 22, 2016
C-H activation reactions as useful tools for medicinal chemistsEduardo J E Caro-Diaz, Mariangela Urbano, Daniel J Buzard, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2010
Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligandsBrad M Savall, James P Edwards, Jennifer D Venable, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2006
Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligandsAlice Lee-Dutra, Kristen L Arienti, Daniel J Buzard, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2013
Kinetics of 5-HT2B receptor signaling: profound agonist-dependent effects on signaling onset and durationDavid J Unett, Joel Gatlin, Todd L Anthony, et al.
Bioorganic & Medicinal Chemistry Letters|December 24, 2014
Design and synthesis of new tricyclic indoles as potent modulators of the S1P1 receptorDaniel J Buzard, Thomas O Schrader, Xiuwen Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|August 5, 2014
Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonistsDaniel J Buzard, Sun Hee Kim, Juerg Lehmann, et al.
Bioorganic & Medicinal Chemistry Letters|June 7, 2015
Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist seriesSangdon Han, Sanju Narayanan, Sun Hee Kim, et al.
Pageof 2